Business Wire - August 21, 2006
The data, which were presented by Calvin Harley, Ph.D., Geron's chief scientific officer, and co-authored by collaborating scientists at the Geffen School of Medicine at UCLA, confirm and extend earlier findings that TAT0002 enhances the function of key immune cells from HIV/AIDS donors. The results show that TAT0002 stimulates RANTES, MIP1-alpha and MIP1-beta, molecules that attract other immune cells to assist in the anti-viral response.
As in previous functional studies, the activity of TAT0002 was blocked by co-treatment with a potent and specific telomerase inhibitor, suggesting that TAT0002 works through telomerase activation. TAT0002 was previously shown to stimulate the production of IFN-gamma -- a molecule involved in the anti-viral response of cytotoxic CD8 T-cells specific for the HIV-1 AIDS virus -- and to enhance the ability of the CD8 cells to proliferate and kill HIV-1-infected CD4 cells.
Dr. Harley also presented data showing that TAT0002 is orally bioavailable in animals. These studies, in conjunction with pilot toxicology results, suggest that therapeutic blood levels of TAT0002 can be achieved with safe, oral doses of TAT0002.
"The new studies demonstrate that our orally available telomerase activator drug broadly reactivates anti-HIV immunity in AIDS patients' lymphocytes," said Thomas Okarma, Ph.D., M.D., Geron's president and chief executive officer. "The lymphocytes are the primary mechanism for containing HIV infection early in the course of the disease. Over time, telomere loss in these cells results in the gradual decline of their anti-HIV function, leading to clinical disease progression. Our hope is to use TAT0002 to prevent this immune decline and thereby prevent HIV progression."
TAT0002 is being developed at TA Therapeutics Ltd., a joint venture between Geron Corporation and the Biotechnology Research Corporation, a company established by the Hong Kong University of Science and Technology (HKUST). For more information on HKUST, visit www.ust.hk.
Geron is a Menlo Park, Calif.-based biopharmaceutical company that is developing and intends to commercialize first-in-class therapeutic products for the treatment of cancer and degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. Geron's products are based on the company's core expertise in telomerase biology and human embryonic stem cells. For more information, visit www.geron.com.
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding future applications of Geron Corporation's telomerase activator compound constitute forward-looking statements involving risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, need for additional capital, reliance on collaborators, need for regulatory approvals or clearances, and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron's periodic reports, including the quarterly report on Form 10-Q for the quarter ended June 30, 2006.
CONTACT:
Geron Corporation | David L. Greenwood, CFO, 650-473-7765 | info@geron.com
or
Noonan Russo
David Schull, 858-546-4810 (Media) | david.schull@eurorscg.com
Sharon Weinstein, 212-845-4271 (Investors) | sharon.weinstein@eurorscg.com
SOURCE: Geron Corporation
060821
BW060828
Copyright © 2006 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .